Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers

Merck (MRK) shares have been on a roll the past year, up nearly 50% to more than $80 in the past year. Yet, despite outstanding fourth quarter and full-year results, the more than $43 billion pharma giant may be on the lookout for acquisitions to help spur growth.